Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong
Vaccines · 17.10.2023 · 11 (10) · 1605
DOI: 10.3390/vaccines11101605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 17.10.2023. Verfasst von Yingcheng Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese University of Hong Kong Direct Grant for Research, Direct Grant for Research (The Chinese University of Hong Kong).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Two respiratory syncytial virus (RSV) vaccines (AREXVY® and ABRYSVO®) were recently approved for older adults in the US. This study aimed to evaluate the cost-effectiveness of AREXVY® and ABRYSVO® from the Hong Kong public healthcare provider’s perspective. A two-year decision-analytical model was developed to examine the outcomes of a single RSV vaccination (AREXVY® or ABRYSVO®) compared to no vaccination. Primary outcomes included RSV-related health outcomes, direct medical costs, quality-adjusted life-year (QALY) loss, and incremental cost per QALY (ICER). RSV vaccines are not yet marketed in Hong Kong, base-case analysis, therefore, benchmarked US RSV vaccine prices at 4 levels (25%, 50%, 75%, 100%). AREXVY® and ABRYSVO® (versus no vaccination) gained 0.000568 QALY and 0.000647 QALY, respectively. ICERs of ABRYSVO® (26,209 USD/QALY) and AREXVY® (47,485 USD/QALY) were lower than the willingness-to-pay threshold (49,594 USD/QALY) at 25% US vaccine price. The RSV attack rate was a common influential factor at all vaccine price levels. The probabilities of AREXVY® and ABRYSVO® to be most cost-effective were 0.10% and 97.68%, respectively, at 25% US vaccine price. Single vaccination of ABRYSVO® or AREXVY® for older adults appears to gain QALYs over 2 years in Hong Kong. The cost-effectiveness of AREXVY® and ABRYSVO® is subject to vaccine price and RSV attack rate.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
ORCID-Profile: Yingcheng Wang, Ginenus Fekadu, Joyce H S You
Förderung
- Chinese University of Hong Kong Direct Grant for Research
- Direct Grant for Research (The Chinese University of Hong Kong)
Zitieren
APA
Wang, Y., Fekadu, G., & You, J. H. S. (2023). Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong. Vaccines, 11(10), 1605. https://doi.org/10.3390/vaccines11101605
Vancouver
Wang Y, Fekadu G, You JHS. Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong. Vaccines. 2023;11(10):1605. doi:10.3390/vaccines11101605
BibTeX
@article{Wang2023,
author = {Wang, Yingcheng and Fekadu, Ginenus and You, Joyce H S},
title = {Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {10},
pages = {1605},
doi = {10.3390/vaccines11101605}
}
EUVIMED